United States - English - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 400 mg in 1 ml - tagitol v is indicated for use in adult patients for use in computed tomography (ct) colonography as a fecal tagging agent. tagitol v is contraindicated in patients with:    -   known or suspected perforation of the gastrointestinal (gi) tract;    -   known obstruction of the gi tract;    -   high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis;    -   high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation;    -   known hypersensitivity to barium sulfate or any of the excipients of tagitol v. risk summary tagitolv is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . risk summary tagitol v is not absorbed systemically by the mother following oral administration and breastfeedin

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 400 mg in 1 ml - varibar thin honey is indicated for modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients. varibar thin honey is contraindicated in patients with: - known or suspected perforation of the gastrointestinal (gi) tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk of aspiration such as those with known or suspected tracheo-esophageal fistula or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of varibar thin honey risk summary varibar thin honey is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. risk summary varibar thin honey is not absorbed systemically by the mother following oral administration, and breastfeeding is not expected to result in exposure of the infant to the drug. the efficacy of varibar thin honey in pediatric patients is based on successful opacification of the pharynx during modified barium swallow examinations [see clinical pharmacology (12.1)] . safety and dosing recommendations in pediatric patients are based on clinical experience. varibar thin honey is contraindicated in pediatric patients with trachea-esophageal fistula. [see contraindications (4)]. pediatric patients with a history of asthma or food allergies may be at increased risk for development of hypersensitivity reactions [see warnings and precautions (5.1)]. monitor patients with cystic fibrosis or hirschsprung disease for bowel obstruction after use [see warnings and precautions (5.3)] . clinical studies of varibar thin honey did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 400 mg in 1 ml - varibar honey is indicated for modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients 6 months of age and older. varibar honey is contraindicated in patients with: - known or suspected perforation of the gastrointestinal (gi) tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk of aspiration such as those with known or suspected tracheo-esophageal fistula or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of varibar honey risk summary varibar honey is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. risk summary varibar honey is not absorbed systemically by the mother following oral administration, and breastfeeding is not expected to result in exposure of the infant to the drug. the efficacy of varibar honey in pediatric patients above 6 months of age is based on successful opacification of the pharynx during modified barium swallow examinations [see clinical pharmacology (12.1)] . safety and dosing recommendations in pediatric patients above 6 months of age are based on clinical experience. varibar honey is contraindicated in pediatric patients with trachea-esophageal fistula [see contraindications (4)] . pediatric patients with a history of asthma or food allergies may be at increased risk for development of hypersensitivity reactions [see warnings and precautions (5. 1)] . monitor patients with cystic fibrosis or hirschsprung disease for bowel obstruction after use [see warnings and precautions (5.3)] . clinical studies of varibar honey did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate .81 g in 1 g - varibar thin liquid is indicated for modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients. varibar thin liquid is contraindicated in patients with: - known or suspected perforation of the gastrointestinal (gi) tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk of aspiration such as those with known or suspected tracheo-esophageal fistula or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of varibar thin liquid risk summary varibar thin liquid is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. risk summary varibar thin liquid is not absorbed systemically by the mother following oral adminis

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 20 mg in 1 ml - readi-cat 2 and readi-cat 2 smoothies are indicated for use in computed tomography (ct) of the abdomen to delineate the gastrointestinal (gi) tract in adult and pediatric patients. readi-cat 2 products are contraindicated in patients: - with known or suspected perforation of the gi tract - with known obstruction of the gi tract - at high risk of gi perforation such as those with a recent prior gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to pelvis - at high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of readi-cat 2 or readi-cat 2 smoothies risk summary readi-cat 2 products are not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. risk summary readi-cat 2 products are not absorbed systemically by

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 400 mg in 1 ml - varibar pudding is indicated for modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients 6 months of age and older. varibar pudding is contraindicated in patients with: - known or suspected perforation of the gastrointestinal (gi) tract; - known obstruction of the gi tract; - high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis; - high risk for aspiration such as those with known or suspected tracheo-esophageal fistula or obtundation; - known hypersensitivity to barium sulfate or any of the excipients of varibar pudding. risk summary varibar pudding is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. [see clinical pharmacology (12.3)] risk summary varibar pudding is not absorbed syste

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 400 mg in 1 ml - varibar nectar is indicated for use in modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients. varibar nectar is contraindicated in patients with: - known or suspected perforation of the gi tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent prior gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk for aspiration such as those with known or suspected tracheo-esophageal fistula or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of varibar nectar risk summary varibar nectar is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . risk summary varibar nectar is not absorbed systemically by the mother following oral a

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 980 mg in 1 g - e-z-hd is indicated for use in double-contrast radiographic examinations of the esophagus, stomach and duodenum to help visualize the gastrointestinal (gi) tract in patients 12 years and older. e-z-hd is contraindicated in patients: - known or suspected perforation of the gi tract - known obstruction of the gi tract - at high risk of gi perforation such as those with a recent prior gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - at high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation - with known severe hypersensitivity to barium sulfate or any of the e-z-hd excipients risk summary e-z-hd is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. risk summary e-z-hd is not absorbed systemically by the mother following oral administration, and breastfeeding is not

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 0.6 g in 1 ml - liquid e-z-paque is indicated for use in single contrast radiographic examinations of the esophagus, stomach, and small bowel to visualize the gastrointestinal (gi) tract in adult and pediatric patients. liquid e-z-paque is contraindicated in patients with the following conditions: - known or suspected perforation of the gi tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of liquid e-z-paque risk summary liquid e-z-paque is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . risk summary liquid e-z-pa

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 960 mg in 1 g - e-z-paque is indicated for use in single contrast radiographic examinations of the esophagus, stomach, duodenum and small bowel to visualize the gastrointestinal tract (gi) in adult and pediatric patients. e-z-paque is contraindicated in patients with the following conditions: - known or suspected perforation of the gi tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent prior gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation - with known severe hypersensitivity to barium sulfate or any of the excipients of e-z-paque risk summary e-z-paque is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . risk summary e-z-paque is not absorb